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Abstract
Several case reports suggest that non-steroidal anti-inflammatory drugs (NSAIDs) may be
associated with thrombotic microangiopathy (TMA). We conducted a matched case-control
study with linked administrative healthcare data in Ontario, Canada to assess the relationship
between TMA hospitalization and recent exposure to prescription NSAIDs versus
acetaminophen (where the latter was a referent group with no known association with TMA).
Cases and controls were drawn from a source population of adults who filled a prescription
for NSAIDs or acetaminophen between 1996 and 2015 (restricted to adults with prescription
drug benefits). Cases comprised individuals hospitalized with TMA between 1996 and 2015.
Controls were matched to cases (4:1) on demographic and medical risk factors. Cases (n=38)
were less likely to have received a recent prescription for NSAIDs relative to acetaminophen
(adjusted odds ratio 0.37, 95% confidence interval 0.16-0.84). Results were similar in two
additional analyses with alternative referent groups. Overall, the results of this study do not
support a harmful association between NSAID use and TMA.
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Chapter 1

1

Introduction

Non-steroidal anti-inflammatory drugs (NSAIDs), are commonly used analgesic and antiinflammatory agents, and one of the most widely used classes of drugs in the world.1,2
Many studies have investigated associations between NSAID use and a wide variety of
adverse medical reactions. Up to 25% of all reported adverse drug events may be
associated with NSAID use, and the risk of adverse drug events increases with age.3
Thrombotic microangiopathy (TMA) describes a rare hematological disorder
characterized by thrombocytopenia (a low concentration of blood platelets) and
microangiopathic hemolytic anemia (a low concentration of red blood cells due to a
rupture of those cells). Several major organ systems can be damaged by TMA, including
the central nervous, cardiovascular and renal systems.4–6 Identifying drugs associated
with TMA development is a relatively novel area of research. Its existence is justified by
the clinical severity of the disease, the abundance of drugs that could be culprits in druginduced TMA, the high frequency of exposure to these drugs, and the lack of
understanding of drug-induced TMA etiology and pathogenesis.7 While NSAIDs have
been linked with TMA in several case reports, this potential association has yet to be
investigated in analytic studies.8–13 Therefore, we conducted a matched case-control study
to assess whether a case of TMA was more likely to be associated with a prior
prescription of NSAID compared to a referent prior prescription of acetaminophen. The
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study sample consisted of Ontario residents who had a prescription NSAID or
acetaminophen dispensed at an outpatient pharmacy between 1991 and 2015.

3

Chapter 2

2

Background and Literature Review

2.1 Non-steroidal anti-inflammatory drugs (NSAIDs)
Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of drugs used for a variety
of symptoms such as pain, fever, rheumatic, and inflammatory disorders.14–16 NSAIDs
work by inhibiting prostaglandin synthesis.17 Prostaglandins are lipid biological factors
that behave similarly to hormones and carry out a great number of functions (including
inflammation onset) when interacting with specific prostaglandin receptors native to
different cell types.17 Prostaglandins are derived from arachidonic acid through the action
of cyclooxygenase (COX) enzymes, classified as COX-1 or COX-2. The resulting
inflammation and pain alleviation is a product of terminating prostaglandin synthesis by
cyclooxygenase (COX) enzymes.14–17 Certain NSAIDs will non-selectively inhibit both
COX-1 and COX-2 enzymes, while the goal of contemporary NSAIDs seem to be
selective COX-2 inhibition. COX-2 is believed to be the root of inflammation and pain
response while sidestepping COX-1 may mitigate unnecessary adverse gastrointestinal
outcomes.14,15,18
NSAIDs are undisputedly among the most widely used medications in the world, with
over 30 million users daily.1,2 The adverse outcomes have the potential to affect most, if
not all, major physiological systems in the human body, including cardiovascular,
gastrointestinal, and renal systems.2,19 NSAIDs are relatively inexpensive drugs on the

4

market to both manufacturers and consumers. However, adverse events associated with
this class of drugs can be costly to the healthcare system.2,15 Studies in the United States
indicate gastrointestinal complications from NSAID use have caused over 100,000
hospitalizations, over 16,000 deaths, and over $500 million in healthcare costs.20

2.2 Thrombotic microangiopathy (TMA)
Thrombotic microangiopathy (TMA) has several causes and is a clinical state
characterized by thrombocytopenia and microangiopathic hemolytic anemia and may also
be associated with acute kidney injury, fever, and acute neurological symptoms. TMA is
further classified as Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic
Uremic Syndrome (HUS), which share many similar clinical symptoms but can differ in
their risk factors.4–6

2.2.1

Thrombotic thrombocytopenic purpura (TTP)

Thrombotic thrombocytopenic purpura (TTP) is a relatively severe form of TMA, with a
mortality rate of up to 90% unless promptly treated with plasma exchange (PLEX).4,21,22
The pathology of TTP can be attributed to deficiency in ADAMTS13 (A Disintegrin And
Metalloprotease with a ThromboSpondin type 1 motif, member 13) protease, which
cleaves von Willebrand factor into short multimers. Low ADAMTS13 activity
perpetuates the presence of long multimers of von Willebrand factor, which can cause
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platelets to aggregate and form clots in the small blood vessels of the body.6,21,22 As a
consequence, the features of TTP include thrombocytopenia (a consumption of platelets),
neurological disorders (confusion, impaired vision, encephalopathy, coma), fever,
jaundice, acute kidney injury, and heart failure. A diagnosis of TTP is supported by
evidence of a severe deficiency of ADAMTS13 activity (<5%) and the presence of IgG
antibody inhibitors.21,23–26
The estimated incidence of TTP is 2 to 11 cases per 1,000,000 persons each year.21,22,27
The reasons for TTP may be congenital, acquired, or idiopathic. Congenital and acquired
forms of TTP most often relate to ADAMTS13 deficiency.22 There are also instances
where there is no recognized cause for the TTP making it idiopathic.21,22,27,28
Biologically, in most cases of TTP there is antibody inhibition of ADAMTS13 29,30 The
root cause of inhibitory antibodies to ADAMTS13 is not well understood. Other factors
implicated in the pathogenesis of TMA include exposure to shiga-toxin, endothelial
dysfunction, and drug-mediated events.31,32

2.2.2

Hemolytic uremic syndrome (HUS)

Hemolytic uremic syndrome (HUS) shares many clinical manifestations with TTP, but
the focus is placed on acute kidney injury (which when most severe requires treatment
with dialysis) and pathological infection by diarrhea-positive toxin producing bacteria
(shiga-toxin and verocytoxin). A small portion of patients (roughly 10%) do not present
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with diarrhea (diarrhea-negative) prior to TMA-associated symptoms, who have a worse
prognosis than others who present with diarrhea.33,34
Diarrhea-positive HUS occurs most commonly in children, specifically those below the
age of 5 years. Various sources report an annual incidence of 0.2-3.4 cases per 100,000
persons per year in Germany, up to 8 cases per 100,000 persons per year in North
America, and 1.4-3.1 cases per 100,000 persons per year in Canada.6,21,33,35–37

2.3 Treatment of TMA disorders
Plasma exchange (PLEX) is a therapy that dramatically improves survival in TTP; for
this reason there is a low threshold to start PLEX when TTP is suspected.21,38 It is
common for patients to receive multiple rounds of PLEX over several days before disease
remission. Relapse, defined as reoccurrence of TTP more than 30 days from the previous
episode, is observed in 20%-50% of patients.21,26,34,39–41 It is important to identify risk
factors and the root cause of TMA to effectively prevent and manage relapses.
Along with dialysis, PLEX may also be used in the treatment of HUS. Furthermore,
evidence from some studies supports the use of rituximab as treatment in immunemediated TTP. 21,33,42,43 Other treatment options include aspirin, dipyridamol, or
glucocorticoids; however, patient outcomes do not seem to differ statistically or clinically
with the inclusion of these drugs in the treatment regime.44,45
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2.4 Long-term outcomes of TMA
Short-term outcomes of TMA have substantially improved with the use of PLEX therapy.
Several important complications persist beyond the 6 months following TMA. First and
foremost, TMA can relapse, at a rate that varies between 8%-84%, and seems to increase
with increasing length of follow-up.46,47 Roughly 10% of all deaths in the 3 years
following TMA have been attributed to a TMA relapse.32,48 Other long-term outcomes
after TMA treated with plasma exchange include chronic kidney disease, hypertension,
stroke, depression, preeclampsia, reduced neurocognitive function, and reduced healthrelated quality of life (indicated by lower physical component summary scores and/or
mental component summary scores).46,47,49–52

2.5 Drug-induced TMA
Adverse drug events are well recognized as a potential cause of TMA.7,53 Drug-induced
thrombotic microangiopathy (DITMA) is formed under two major mechanisms. Immunerelated DITMA occurs when the drug prompts the generation of antibodies that interacts
with cells, eventually leading to TMA associated symptoms such as platelet
aggregation.54,55 Toxic-related DITMA is often dependent on drug dose. This type of
DITMA may develop from tissue injury as a direct consequence of patients ingesting
large quantities of a drug over a short period of time.56
DITMA occurs in both children and adults. Analyses of the Oklahoma Thrombotic
Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) registry suggest
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5% of all TMA cases are due to drugs. However, the true incidence of DITMA is difficult
to ascertain due to overlap with other prominent risk factors, the absence of appropriate
diagnostic tools, and lack of understanding of pathological mechanisms.7,53

2.6 Drugs associated with TMA
In a systematic review of published DITMA case reports, 78 drugs were identified as a
potential cause of TMA. However, the evidence only qualitatively supports 22 (28%) of
these claims.7 Drugs most commonly associated with TMA are those indicated for
malaria (Quinine), cancer (gemcitabine, bevacizumab, mitomycin, oxaliplatin,
pentostatin, sunitinib), immunosuppression (cyclosporine, sirolimus, tacrolimus),
antibiotics (trimethoprim-sulfamethoxazole), and drugs of abuse (cocaine, ecstasy,
oxymorphone).7,53

2.7 Risk factors for TMA
TMA occurs more commonly in women than men.57–59 It is unclear as to why women
have a higher risk of TMA, but studies with non-selective samples often show higher
proportions of women with TMA as opposed to men.57,60,61
Malignant hypertension potentially affects TMA on two fronts: first, reduced
ADAMTS13 activity has been observed in malignant hypertension, and second,
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endothelium damage due to malignant hypertension may trigger release of von
Willebrand factors.62–64
TMA is often induced in various late-stage cancers, such as prostate, breast, lung, and
ovarian cancers. The pathophysiology of cancer-induced TMA is not well understood,
but many similar clinical symptoms are present in both TMA and cancer, most commonly
microangiopathic hemolytic anemia.65–68
Antibodies to ADAMTS13 may form in patients with recent transplants and in patients
diagnosed with auto-immune diseases (e.g. systemic lupus erythematosus, HIV). As
previously discussed, the underlying pathophysiology of TMA is not well understood.69–
73

Fakhouri et al. found a considerable risk for TMA during pregnancy in a review
published in 2010.74 The incidence of HUS is estimated to be 1 in 25,000 pregnancies,
slightly higher than the general population. However, very little is known about the
pathophysiology of pregnancy related TMA, 74,75

2.7.1

Shiga toxin-producing Escherichia coli infection

Shiga toxin-producing Escherichia coli (STEC) infections are characterized by the
presence of at least one phage-encoded Shiga toxin gene (stx1 or stx2). STEC infections
are associated with an array of diseases, ranging from mild gastrointestinal disturbances
to clinically severe conditions, including HUS.76 A large proportion of patients with
critical STEC infections also develop conditions commonly associated with infection
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such as sepsis including septic shock.77 An English study by Byrne et al. documented
3,717 suspected cases of STEC infection between 2009 and 2012. 3,267 (90.7%) cases of
infection were confirmed and 215 (6.4%) cases progressed to HUS. The HUS cases were
predominately women and children, and the highest proportion of HUS cases occurred in
females under the age of 14.78 Rural residents were more likely to be infected; the
incidence of STEC infections was roughly 4 fold higher in individuals residing in rural
areas compared to urban residents.78

2.8 NSAID indications and characteristics of NSAID users
The main indications for NSAIDs are pain, inflammation, and associated diseases of an
acute and chronic nature. For example, NSAIDs are commonly prescribed for patients
suffering from arthritic conditions (e.g. osteoarthritis, rheumatoid arthritis) and other
autoimmune diseases.14,15,79
Older adults are the most frequent NSAIDs users. A meta-analysis of 16 studies by
Gabriel et al. found that roughly 40% of NSAID prescriptions were for patients over the
age of 60.80
The Alabama NSAID Patient Safety Study administered surveys to understand patterns
of NSAID use prescribed by 48 participating primary care physician practices. The
results were published in 2007 and summarized findings based on a sample size of 404
Americans comparing black and white patients.20 Responders were mostly women (73%)
and white (68%), with a mean age of 73 years in both groups. The study found that black
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NSAID users were more likely to belong to a lower socio-economic status (cut-off was
selected at annual household income of $20,000). The likelihood of living in a rural
residence did not differ between black and white NSAID users.20
While higher doses of NSAIDSs are obtained through a medical prescription, several
lower dose NSAIDs can be purchased over-the-counter without a prescription. A study of
229 447 French patients described and compared the characteristics of over-the-counter
and prescription NSAID users. About 52% of patients in the study received at least one
prescription for a NSAID. Compared to over-the-counter NSAID users, prescription
strength NSAID users were older (mean age 39.9 vs. 47.4), and were more likely to have
at least one long-term illness (18.9% vs. 27.6) (conditions considered as long-term
illnesses included stroke, severe arterial hypertension, coronary artery disease, severe
heart failure, arrhythmia, heart valve disease, and congenital heart defects). Both groups
had similar portions of women (56.7% versus 53%).81

12

Chapter 3

3

Rationale

3.1 TMA association with NSAID usage
We performed a comprehensive review of the literature to summarize the current state of
evidence regarding the association between TMA and NSAID exposure. We used the
bibliographic databases Pubmed, EMBASE, Google Scholar, and Web of Science. Our
search strategy for each database is described in appendix A. We identified 8 case reports
suggesting a possible link between TMA and NSAID usage.
Several generic methods have been used to assess the quality of reports to gain insight
into the potential causality of an adverse drug event (e.g. Naranjo, Jones). No measure
has been shown to better than the others, and in most cases the measure results in a
conclusion that the drug has a ‘possible’ or ‘probable’ chance of causing the adverse drug
event.82,83
In our case, we evaluated the quality of the 8 case reports using an existing framework to
assess drug-induced TMA (see appendix B). The results of this appraisal are found in
table 1. In summary, TMA development was linked to Ibuprofen in 4 cases.8–10,84 None of
the 4 patients reported exposure to other risk factors for TMA, and exhibited telltale signs
of TMA including hemolytic anemia, a low platelet count, acute kidney injury, an altered
mental state, and low ADAMTS13 levels. Another published case report study of a 58year old woman described a possible link between ketorolac trometamol and TMA.12 One
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case report published by Trice et al. attributed TMA development in a 64-year old man to
treatment with D-penicillamine (an antibiotic); however, the patient had received
naproxen (an NSAID) prior to receiving D-penicillamine.85 The NSAIDs diclofenac and
pranoprofen were each reported to be associated with TMA in two separate case
reports.13,86 In a review of DITMA, Al-Nouri et al. listed 2 case reports of ibuprofen and
ketorolac under immune-mediated TMA in their supplementary table S3.7 These case
reports were captured within the scope of our literature review.
Beyond the published literature, we searched the European Database and Suspected
Adverse Drug Reaction Reports, which records reports from the European Economic
Areas (EEA). Collectively, there were a total of 54 cases of TMA with an NSAID
identified as a suspected cause. Ibuprofen accounted for the majority of these cases (40),
followed by diclofenac (12) and naproxen (2). The age of these patients ranged from less
than 1 year to over the age of 65. We also searched (i) Health Canada’s Canada Vigilance
Program database and (ii) the Food and Drug Administration’s Adverse Event Reporting
System (FAERS) database, but these searches did not yield any reports. We recognize we
have may have missed potentially reports of interest within these databases, given our
limited level of access and difficulties with how the data are organized.
We contacted manufacturers of NSAIDs (Pfizer, Novartis, and Bayer) via telephone
and/or e-mail to inquire whether they had any documented cases of TMA associated with
their NSAID drugs. Whenever a valid response was received, we were simply referred to
publicly available information that we had already reviewed.
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It appears the current evidence supporting an association between NSAIDs and TMA is
limited to case report studies. While case reports are helpful in detecting novel events and
are hypothesis generating, they are limited in eliciting cause and effect relationships, and
they are also limited by several forms of bias and poor generalizabilitys.87 We were
unable to perform an in-depth review of two of the eight reports due to language barriers
(one report was written in Italian and one report was written in Spanish) and limited
access to full articles (the articles were published in 1974 and 1989). The reports have
been referenced in more recent case reports but a detailed analysis of the reports was not
made.
Five of the remaining six studies reviewed did not document an alternative condition or
drug exposure which could have led to TMA, and it was not clear from the report
whether discontinuation of the NSAID (or a reduced dose of NSAID) was followed by an
improvement in TMA symptoms.
None of the case reports provided information as to whether reintroduction of a NSAID
after a TMA episode resulted in a TMA reoccurrence.
Furthermore, the potential pathophysiologic mechanism by which of NSAIDs may cause
TMA is not well understood. Some have hypothesized that the potential association
between TMA and NSAID lies within the formation of autoantibodies against
ADAMTS13.84
Thus, an important gap exists in the literature with respect to the possible link between
NSAIDs and TMA.
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3.2 Research objective and hypothesis
This study was conducted to investigate whether a TMA hospitalization was more likely
to be associated with a recent prior prescription for NSAID compared to a recent prior
prescription of acetaminophen, the latter being the referent drug with no known
association with TMA. To address this objective, we conducted a retrospective matched
case-control study using health administrative data in the province of Ontario. Given the
current state of evidence, we hypothesized that exposure to NSAIDs, relative to
acetaminophen, would be associated with a higher incidence of TMA.
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Table 1.
Case report evaluation for NSAID associated TMA
NSAID

Citation

Year

Patient sex

Level of

published

and age in

evidence1

years
Diclofenac

Claros González I, Baños

1989

Gallardo M, Casal Alvarez F,

Male,

5

middle aged

Argüelles Toraño M.
Systemic thrombotic
microangiopathy secondary
to diclofenac. Med Clínica.
1989;92(10):396.
Ibuprofen

Catizone L, Santoro A,

1974

Female, 55

5

2007

Female, 44

2

2013

Male, 21

2

Scialfa G, Cagnoli L, Fabbri L.
Thrombotic
thrombocytopenic purpura
due to administration of
Ibuprofen. Minerva Nefrol.
1974;21(6):439-444.
Ibuprofen

Schoenmaker NJ, Weening
JJ, Krediet RT. Ibuprofeninduced HUS. Clin Nephrol.
2007;68(3):177-178.

Ibuprofen

Oregel KZ, Ramdial J, Glück
S. Nonsteroidal Antiinflammatory Drug Induced
Thrombotic

17

Thrombocytopenic Purpura.
Clin Med Insights.
2013;6:19-22.
doi:10.4137/CMBD.S12843.
Ibuprofen

Benmoussa J, Chevenon M,

2016

Male, 37

2

1993

Female, 58

2

1983

Male, 64

3

Nandi M, Forlenza TJ,
Nfonoyim J. Ibuprofeninduced thrombotic
thrombocytopenic purpura.
Am J Emerg Med.
2016;34(5):942.e5-e7.
doi:10.1016/j.ajem.2015.10.
044.
Ketorolac

Randi ML, Tison T, Luzzatto

Tromethamine

G, Girolami A. Haemolytic
uraemic syndrome during
treatment with ketorolac
trometamol. BMJ.
1993;306(6871):186.

Naproxen

Trice JM, Pinals RS, Plitman
GI. Thrombotic
thrombocytopenic purpura
during penicillamine
therapy in rheumatoid
arthritis. Arch Intern Med.
1983;143(7):1487-1488.
doi:10.1001/archinte.1983.
00350070215039.
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Pranoprofen

Okura H, Hino M, Nishiki S,

1999

Female, 25

2

et al. Recurrent hemolytic
uremic syndrome induced
by pranoprofen. Rinsho
Ketsueki. 1999;40(8):663666.
1

Case reports are given a level from 1 to 5 depending on how many causal criteria the case fulfills; 1 =
definite evidence of a causal relationship, 2 = probable, 3 = possible, 4 = unlikely, 5 = unsuitable for
review. A more detailed explanation is provided in appendix B.
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Chapter 4

4

Methods

4.1 Study design and setting
We conducted a retrospective matched case-control study using administrative data in the
province of Ontario, linked at the Institute of Clinical Evaluative Sciences (ICES). Cases
(individuals who were hospitalized for TMA between 1996 and 2015) and controls
(described below) were identified from a source population of Ontario residents who (i)
were prescribed NSAIDS or acetaminophen between 1996 and 2015 and (ii) had
universal drug coverage during this time (in Ontario, universal drug coverage is granted
to Ontario residents who are older than age 65, to those living in a long-term-care facility
or a home for special care, and to those enrolled in the Home Care program, the Trillium
Drug Program, Ontario Works, or the Ontario Disability Support Program). We selected
this study design given TMA is a rare disease.
This study was conducted according to a pre-specified protocol, which was approved by
the Research Ethics Board at the Sunnybrook Health Sciences Centre in Toronto,
Ontario. The reporting of the study adheres to the Reporting of studies Conducted using
Observational Routinely-collected Data (RECORD) guideline (appendix C).
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4.2 Data sources
This study was conducted using administrative healthcare databases linked at the ICES
Western site in London, Ontario. The study was conducted primarily using the following
four databases:
1) Registered Persons Database
The Registered Persons Database (RPDB) is a population-based registry managed by the
Ministry of Health and Long-Term Care (MOHLTC) in Ontario, Canada. The RPDB is
essentially a comprehensive listing of the unique health numbers that have been issued to
individuals eligible for coverage since its conception, and the purpose of the database is
to direct publicly funded health care services covered under the Ontario Health Insurance
Plan. When new RPDB data arrive at ICES, information regarding a potential patient’s
identity is removed and each unique health number is encrypted into an anonymous
identifier, the ICES Key Number (IKN). The IKN is a unique identifier that is used to
link patient data across databases in ICES. We used the RPDB database to obtain
demographic information including a patient’s date of birth, sex, income categories
(sorted into 5 quintiles in order of ascending income levels), urban or rural residence
status, and date of death.

2) Ontario Drug Benefit
The Ontario Drug Benefit (ODB) Program is a publicly funded program that provides
financial assistance for medication costs. The ODB records all outpatient drug
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prescriptions dispensed to patients who are eligible for this program, specifically, Ontario
residents aged 65 years and older, those living in a long-term-care facility or a home for
special care, and those enrolled in the Home Care program, the Trillium Drug Program,
Ontario Works, or the Ontario Disability Support Program. We used this database to
ascertain exposures to any of our study drugs and to any baseline medications.

3) Canadian Institute for Health Information – Discharge Abstracts Database
The Canadian Institute for Health Information – Discharge Abstract Database (CIHIDAD) contains patient-level demographic, diagnostic, medical procedural, and other
administrative information (e.g. physician responsible for the patient) for hospitals across
Ontario. The structure of the database allows an assignment of up to a maximum of 25
diagnoses allocated to a single hospitalization event. Diagnoses made prior to 2002 are
recorded using the International Classification of Diseases, ninth revision (ICD-9). Since
then the tenth revision of the coding has been used to record diagnosis information. We
used this database to identify all diagnoses of TMA from 1991 to the latest update, which
includes up to March of 2015. We also used this database to ascertain information on
baseline comorbidities.

4) Ontario Health Insurance Plan
The Ontario Health Insurance Plan (OHIP) database contains medical service claims
made by healthcare professionals, including physicians, for patients who are residents of
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Ontario. Ontario physicians are reimbursed for the services they are documented as
providing to specific patients on specific days. The OHIP database records information
such as the type of service provided, diagnostic information, the healthcare professional
that provided the service, the patient who received the service, the date the claim was
filed, and the associated fee code. It is estimated that 95% of physicians in Ontario utilize
OHIP as their source of income. We used this database to identify any patients who
received plasma exchange treatments between July 1991 to March 2015.

4.3 Patient population selection
Patients who had at least one prescription for an NSAID or acetaminophen dispensed
through Ontario Drug Benefit (ODB) between July 1991 and March 2015 formed the
study base for this case-control study. The data was subsequently linked to the Registered
Persons Database (RPDB) and all patients with an invalid or missing value under the
variables age, sex, or health card number (patient identifying number) were excluded.
Next, we identified all hospitalizations with TMA through linkage to Canadian Institute
for Health Information-Discharge Abstract Database (CIHI-DAD). As we were interested
in new (de novo) episodes of TMA, we excluded patients with evidence of a TMA
diagnosis or patients who received plasma exchange preceding July 1, 1996. The
remaining patients consisted of cases with a hospitalization diagnosis of TMA as defined
from CIHI-DAD (codes presented in appendix D), and potential controls that did not
have a hospitalization diagnosis of TMA as defined from CIHI-DAD.
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4.4 Index date
Cases were assigned an index date representative of the initial date of their
hospitalization for TMA. Index dates fell between July 1, 1996 and March 31, 2015.
Since the remaining patients were not diagnosed with TMA, we sampled the distribution
of index dates from the case population and randomly assigned index dates to the
remaining non-TMA patients based on the same distribution of index dates as cases

4.5 Study population
4.5.1

Cases

We identified all available Ontario patients from our study base with a hospital admission
diagnosis of TMA between July 1, 1996 and March 31, 2015 (codes presented in
appendix D). Patients were restricted to their first admission to a hospital with TMA
diagnosis within our accrual period, and the initial hospitalization with a TMA diagnosis
served as the index date for cases.
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4.5.2

Controls

All individuals from our study base without a TMA diagnosis during our accrual period
were eligible to be selected as controls. Since patients without TMA did not have a date
of diagnosis to serve as an index date, we randomly assigned an index date to the pool of
potential controls based on the distribution of index dates in cases.
Matching is defined as the pairing of cases and controls based on pre-specified
characteristics in order to form similar, if not identical matched sets with respect to said
characteristics.88 The purpose of matching in case-control studies is to increase a study’s
efficiency by ensuring similarity in the distribution of variables between cases and
controls, in particular, the distribution of potential confounders.88,89 We matched 4
controls per case based on the following characteristics: age (± 2 years), sex, index date
(<6 months), rural residence (population less than 10,000), neighborhood income
quintile, and conditions and drugs associated with a higher risk of TMA: malignant
hypertension, systemic lupus erythematosus, HIV, sepsis, and use of quetiapine,
tacrolimus, sirolimus, cyclosporine, clopidogrel, and ticlopidine.
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4.5.3

Exposure

We were interested in patients who had a past prescription of NSAIDs or a past
prescription for acetaminophen, an analgesic drug used for a similar indication but not
suspected to be associated with TMA.

We looked at patients who were exposed to either one, mutually exclusive exposures, to
minimize confounding by indication. For the purposes of this study, patients prescribed
an NSAID were classified as “exposed”, while patients prescribed an acetaminophen
were classified as “unexposed”. Index dates served as the point in time from when we
looked back in time to ascertain exposure, where the drug supply period of the most
recently dispensed NSAID or acetaminophen overlapped with the index date. The
window of time in which we ascertained drug exposure was defined by the variable “day
supply” in ODB, extended by 50%. For example, if a patient had received a prescription
for 30 days worth of drug supply for NSAID or acetaminophen, we would look to see if
they had been hospitalized with TMA within 45 days (30 days + 50%) of the date of
prescription. Given the way we constructed the study sample to efficiently pull data from
our data sources, it was expected we would have a substantial number of patients with no
evidence of an NSAID or acetaminophen dispensed just prior to the index date (i.e. they
had an NSAID or acetaminophen filled between July 1996 and March 2015, but this was
well before or after their index date); such patients were excluded from analysis.
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Patients with evidence of both an NSAID and acetaminophen were excluded from the
analysis so that we could compare mutually exclusive groups.

4.6 Baseline characteristics
Baseline characteristics were assessed using ICD-9 and ICD-10 codes within the five
years prior to the index date, with the exception of primary care physician visits being
assessed in the year prior to the index date (but not in the 30-day period before the index
date to avoid physician encounters possibly related to the TMA; database codes used to
define characteristics are presented in supplementary appendix 2). Baseline outpatient
drug use was ascertained in 120-day period before the index date, as in Ontario the
maximum day supply for a dispensed drug is 100 days.

4.7 Comorbidity indices
Comorbidity can be referred to as the simultaneous existence of disease conditions other
than the disease or outcome of interest. Comorbidity indices are designed to reflect
comorbid burden, which can be used to predict mortality or adjust for as potential
confounders in epidemiological studies.90,91 We considered implementing the Charlson
Comorbidity Index and the John Hopkins Aggregated Diagnostic Groups. The Charlson
Comorbidity Index measures general comorbidity based on the presence of a combination
of diseases for a specific patient. Patients receive scores corresponding to a diagnosed

27

disease, the cumulative scores of all relevant diagnosed diseases represents their
individual Charlson Comorbidity Index. A score of 1 is assigned to the following
conditions: myocardial infarction, congestive heart failure, peripheral vascular disease,
cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective
tissue disease, peptic ulcer disease, mild liver disease, and diabetes. A score of 2 is
assigned to the following conditions: hemiplegia, moderately severe renal disease,
diabetes with organ damage, any tumors within the last 5 years, lymphoma, and
leukemia. A score of 3 is assigned to moderately severe liver disease. Finally, patients
diagnosed with acquired immune deficiency syndrome (AIDs) or metastasized tumors are
assigned a score of 6. 90–93 John Hopkins Aggregated Diagnostic Groups features 32
diagnostic clusters called aggregated diagnostic groups (ADGs), and each disease is
categorized into one of the 32 clusters based on: duration of the condition, severity of the
condition, disease etiology, diagnostic certainty, and specialty care involvement.
Similarly, all baseline conditions are categorized and a cumulative score is derived to
represent risk of mortality.94 Both techniques have been modified to utilize ICD codes for
scoring.91,94 Austin et al. published a study in 2011 that showed superior performance in
model discrimination and calibration for John Hopkins ADG scores as compared to the
Charlson Comorbidity Index.95 This study was performed using the same Ontario datasets
analyzed in our study. For this reason we decided to use the John Hopkins ADG score for
this study.
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4.8 Statistical analysis
We assessed balance of baseline characteristics between case and control groups using
hypothesis testing and standardized differences. Hypothesis testing operates on the null
hypothesis that there are no critical differences between one group over another in terms
of a specific treatment or condition. With respect to baseline assessment, we are testing if
there is evidence to refute the null hypothesis (i.e. if there are indeed differences in means
or proportions between cases and controls) across our selected baseline characteristics.96
The p-value is widely used in hypothesis testing and describes the probability of
obtaining an observation as large as the observed, had the null hypothesis been true. A pvalue of <0.05 can represent considerable evidence against the null hypothesis.97 Another
method we used to compare baseline characteristics is the standardized difference. The
standardize difference statistic measures differences between group means with respect to
pooled standard deviation. A value of greater than 10% or 0.01 can be interpreted as a
meaningful difference between two compared groups.98–100 We initially considered using
standardized differences for its advantageous properties over hypothesis testing in studies
with large sample sizes, however, this was not an issue with the current study.99,100
Therefore, we selected to report p-values over standardize differences. We implemented
generalized estimating equations (GEE) to assess baseline balance between cases and
controls.101
Logistic regression is fundamentally used to model the relationship between a binary
dependent variable and a series of independent variables, but the method can be tailored
to fit the nature of the data that is to be analyzed.102,103 We used conditional logistic
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regression to obtain odds ratios, which provides an effect estimate of the likelihood of
having a recent prescription for an NSAID among patients who were hospitalized with
TMA (binary dependent variable) relative to acetaminophen. Conditional logistic
regression is commonly selected as the statistical analysis when matching is done in a
case control study.104 The main reason for this selection is to provide an estimate that is
less susceptible to the effects of sparse data created by forming multiple strata of matched
pairs as seen in our study.105
We conducted all analyses using SAS version 9.3 (SAS institute, Cary, North Carolina,
USA, 2008)

4.9 Additional analyses
We repeated the analysis with the referent drug hydromorphone instead of
acetaminophen. The purpose of this analysis was to replicate the results of the primary
analysis, as agreement between the two would increase our confidence in the findings.
There is no known association between hydromorphone and TMA.
Another consideration is that some NSAIDs (i.e. ibuprofen) are readily accessible over
the counter and without a physician’s prescription. Exposure to over the counter nonprescription NSAID use in the referent group would reduce differences in exposure
between our comparison groups and reduce our ability to detect a higher risk of TMA
with NSAIDs if an association had indeed existed. This is described as contamination
bias, where the patients in the acetaminophen group were inadvertently exposed to
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NSAIDs, thus diminishing the difference in outcomes between the two exposures.106 To
limit the risk of contamination bias we repeated the analysis with the referent drug as an
ACE-inhibitor instead of acetaminophen, as we expected less over the counter NSAID
use in the setting of ACE-inhibitor use (as using both drugs together is often avoided).
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Chapter 5

5

Results

5.1 Source population and selection of cases and controls
The steps in patient selection are summarized in Figure 1. In brief, the source population
consisted of 3,598,154 individuals who had evidence of a prescription dispensed for
either a study NSAID or acetaminophen at least once anytime between July 1991 and
March 2015, but after we excluded those with invalid or missing age, sex, and Ontario
health card numbers. Next, we excluded 28 individuals with a TMA diagnosis prior to
July 1996. Another 3,673 individuals were excluded due to their receipt of plasma
exchange (939 prior to 1996; after the index date was assigned, 2,734 recipients of
plasma exchange prior to 6 months before their index date). Of the remaining population
of patients (n=3,598,154), we excluded 3,344,893 patients because their index date did
not fall within the duration of their day supply extended by 50% (i.e. they had their
NSAID or acetaminophen dispensed well before or after their index date), and we
excluded 18,282 patients who had an index day fall within the duration of supply of both
a study NSAID and acetaminophen. The patient population prior to matching consisted of
44 cases and 231,234 potential controls. Patients were ‘hard’ matched on binary variables
and for categorical variables (i.e. case and control must have same output). Ultimately,
we were able to match 38 cases of TMA to 152 controls without TMA (1:4) for a final
study population of 190 patients.
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We performed some descriptive analyses to understand the clinical context of this 38
TMA cases. To comply with privacy regulations for minimizing the chance of patient
identification, cells between 1-5 patients are suppressed (reported as ≤5). Cells with a
value of 0 are reported, as there is no one who could be identified. The TMA cases
occurred across 28 different hospitals in Ontario. Within 90 days of their index hospital
admission, 16 of 38 cases (42%) received at least one treatment with PLEX, 6 of 38
(16%) received at least one treatment with dialysis, ≤5 (≤ 13%) of 38 were admitted to an
intensive care unit, and ≤5 (≤ 13%) of 38 died.

5.2 Baseline characteristics
A comparison of baseline characteristics in cases and controls is presented in Table 2.
The average age of patients was 67, and women accounted for two-thirds of the study
sample. Given that we matched on several baseline characteristics, cases and controls
were similar on most characteristics (p-value > 0.05). However, there were observed
differences between cases and controls on the number of visits to a primary care
physician in the year prior to the patient’s index date, and on the John Hopkins
Aggregated Diagnosis Group Score.
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5.3 Primary analysis
19 cases (50%) were exposed to an NSAID and 19 cases (50%) were exposed to
acetaminophen.
The results of the regression analyses comparing TMA among patients prescribed
NSAIDs vs. acetaminophen are presented in Table 3. Patients who were hospitalized with
TMA were less likely to have received NSAIDs compared to acetaminophen (odds ratio
[OR] 0.32, 95% confidence interval [CI] 0.15 – 0.68). Adjusting for baseline
characteristics that differed between cases and controls did not meaningfully change this
result (table 3; OR 0.37, 95% CI 0.16 – 0.84).

5.4 Additional Analyses
We wanted to determine if the reintroduction of NSAIDs after a TMA episode resulted in
reoccurrence of the TMA. We found that of the 19 cases that had NSAIDs prior to their
first TMA episode, 8 (42.1%) received a repeat prescription for NSAIDs in the year
following their TMA-associated discharge date. None of these patients had a rehospitalization with TMA in the 30 days after the follow-up prescription.
We used the active comparator (reference group) acetaminophen in this study, to reduce
concerns about confounding by indication. However, this has implications for the
interpretation of study results. For example, patients who were hospitalized with TMA
were less likely to have received NSAIDs compared to acetaminophen (odds ratio [OR]
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0.32, 95% confidence interval [CI] 0.15 – 0.68). This can be interpreted in several ways,
including that NSAIDs are ‘protective’ in preventing TMA, acetaminophen is ‘harmful’
in causing TMA, acetaminophen is more ‘harmful’ than NSAIDs in causing TMA, or
acetaminophen is less ‘beneficial’ than NSAIDS in preventing TMA, although most of
these possibilities are not supported by our underlying understanding of the biology of
TMA. However, to consider the results in other contexts we repeated the analysis twice
with either hydromorphone or angiotensin converting enzyme inhibitors (ACE-I) (and not
acetaminophen) as the reference group.

5.4.1

Hydromorphone comparator group

A new data cut was performed for this analysis to create a source population consisting of
individuals with an evidence of prescription filling for NSAIDs or hydromorphone. The
exclusions and cohort selection methods were as done for the primary analysis,
comparing NSAIDs to acetaminophen. Ultimately, fewer than six cases were exposed to
hydromorphone, which precluded us from presenting the results of this analysis due to
privacy considerations; however, there was no observed association between NSAID use
and TMA when the referent group was hydromorphone. The limited statistical power of
this analysis meant the estimate was likely not precise enough to be considered
meaningful.
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5.4.2

Angiotensin-converting enzyme inhibitor (ACE-I)
comparator group

This supplementary analysis was done to reduce concerns about over-the-counter NSAID
use in the control group (as NSAIDs are often avoided in the setting of ACE-I use). In a
similar fashion to our other supplementary analysis, a new data cut was performed in
order to create a source population of patients with evidence of a prescription filled for
NSAIDs or ACE-Is. The exclusions and cohort selection methods were identical to that
of the primary analysis, comparing NSAIDs to acetaminophen. The figures and tables
corresponding to patient selection, baseline characteristics, and analysis output can be
found in appendix E, F, and G respectively.
In brief, the source population consisted of 3,442,246 individuals. Patients with a past
diagnosis for TMA (n=80), and history of evidence for plasma exchange (n=3,392) were
excluded. In ascertaining exposure, it was determined that 2,858,914 individuals were not
exposed to either class of study drugs and 49,896 individuals were exposed to both
classes of study drugs simultaneously. Exposure definitions were as done for the primary
analysis. After matching, the final study population consisted of 84 cases matched to 336
controls.
The mean age of patients in the study population was 73. Females accounted for roughly
60% of the study population.
There was no observed association between NSAID use and TMA when the referent
group was ACE-I (odds ratio 0.82, 95% CI 0.45-1.49; selection, baseline characteristics
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and outcomes presented in appendices 3, 4 and 5, respectively). We performed an
analysis adjusting for differences in baseline characteristics (more specifically: cancer,
osteoarthritis, rheumatoid arthritis, John Hopkin’s ADG score and primary care physician
visits), but did not observe a meaningful change in the results (odds ratio 0.72, 95% CI
0.38-1.37).
Figure 1. Flow diagram of patient selection with acetaminophen as the referent
group
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Table 2. Baseline characteristics for patients prescribed NSAIDs or acetaminophen
with and without thrombotic microangiopathy (cases and controls, respectively)
Controls
(n=152)

Cases (n=38)

P-value

Demographics

Age, no. (%)
Median (IQR)

71 (65-79)

71 (61-78)

Mean ± SD

67 ± 16.11

67 ± 16.75

16 - 34

9 (5.9%)

≤5

35 - 44

8 (5.3%)

≤5

45- 54

7 (4.6%)

≤5

55 - 64

11 (7.2%)

≤5

65 - 74

61 (40.1%)

15 (39.5%)

75 - 84

45 (29.6%)

9 (23.7%)

≥ 85

11 (7.2%)

≤5

Women, no. (%)

96 (63.2%)

24 (63.2%)

1.0

Rural residence2, no. (%)

32 (21.1%)

8 (21.1%)

1.0

0.47

0.23

Socioeconomic status3, no. (%)
Quintile 1

28 (18.4%)

7 (18.4%)

1.0

Quintile 2

52 (34.2%)

13 (34.2%)

1.0
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Quintile 3 + 45

40 (26.4%)

10

1.0

Quintile 5

32 (21.1%)

8 (21.1%)

1.0

Primary care physician visits, no. (%)
Median (IQR)

19 (5-15)

14 (7-23)

Mean ± SD

12 ± 11.98

19 ± 17.06

0-2

16 (10.5%)

≤5

3-4

20 (13.2%)

≤5

<0.05

<0.05
5-6

24 (15.8%)

≤5

7-8

14 (9.2%)

≤5

9 - 10

15 (9.9%)

≤5

≥ 11

63 (41.4%)

23 (60.5%)

<0.05

Comorbidities, no. (%)
John Hopkins Aggregated Diagnosis Group Score, no. (%)
Median (IQR)

12 (9-15)

14 (12-16)

Mean ± SD

12 ± 3.77

14 ± 3.43

≤9

44 (28.9%)

<0.05

10 (26.3%)5
10 - 12

41 (27%)
<0.05

13 - 15

42 (27.6%)

14 (36.8%)

≥ 16

25 (16.4%)

14 (36.8%)

Malignant hypertension

≤5

≤5

-

Systemic lupus erythematosus

≤5

≤5

-

Cancer5

Suppressed

≤5

1.0

Renal transplant

≤5

≤5

-
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Osteoarthritis

12 (7.9)

≤5

0.59

Rheumatoid arthritis

12 (7.9)

≤5

0.56

HIV

≤5

≤5

1.0

Sepsis

≤5

≤5

1.0

Medications, no. (%)

1no.:

Quinine

≤5

≤5

-

Quetiapine

≤5

≤5

-

Tacrolimus

≤5

≤5

-

Sirolimus

≤5

≤5

-

Cyclosporine

≤5

≤5

-

Clopidogrel

≤5

≤5

-

Ticlopidine

≤5

≤5

-

Number, IQR: interquartile range, SD: Standardized difference, NSAIDs: Non-steroidal anti-inflammatory drugs.
residence is defined as population < 10,000.
3Quntiles are ranked from lowest to highest (i.e. Quintile 1 = lowest, Quintile 5 = highest).
4P-values are calculated using generalized estimating equations to account for the non-independent correlation
structure.
5Cells are combined or suppressed to avoid reporting numbers ≤5.
2Rural
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Table 3. The association between NSAID use and thrombotic microangiopathy, with
acetaminophen as a reference group. Odds ratios derived from a conditional logistic
regression model
Cases of

Controls

Odds Ratio (95% confidence interval)

TMA
(n=38)

(n=152)

Unadjusted

Adjusted1

Acetaminophen

19 (50%)

37 (24%)

1.0 (referent)

1.0 (referent)

NSAIDs2

19 (50%)

115 (76%)

0.32 (0.15 – 0.69)

0.37 (0.16 – 0.84)

1Adjusted
2NSAIDs:

analysis included the variables John Hopkin’s ADG score and primary care physician visits.
Non-steroidal anti-inflammatory drugs.
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Chapter 6

6

Discussion

6.1 Interpretation of study results
There are over 30 million daily users of NSAIDs worldwide, and there is some evidence
from case-report studies that patients who present with TMA have a recent history of
NSAID use.1,2 We conducted this matched case-control study to better understand
whether NSAID use is associated with a higher risk of hospitalization for TMA. We
found that cases with TMA were less likely to have had a recent prescription for NSAIDS
relative to acetaminophen. More specifically, we observed that the case patients were
nearly 3 times (OR: 0.37) less likely to be exposed to an NSAID relative to
acetaminophen. Furthermore, this association was statistically significant (95% CI: 0.16 –
0.84). We found no association between NSAID use and TMA when we examined two
alternate reference groups. For example, when we compared NSAIDs to ACE-inhibitors,
we observed no significant association [OR of 0.72 (95% CI: 0.38 – 1.37)]. Ultimately,
we were unable to provide any evidence to support a harmful association between
NSAIDs and TMA.
Our findings prompted us to re-examine the case reports.7–10,12,13,85 The most common
reason the reports suggested NSAIDs as the cause of TMA was simply because there was
no other identified cause present. Furthermore, no research to date provides a strong
biological basis for a higher risk of TMA with NSAIDs. This would indicate that, at the
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very least, NSAIDs are not associated with a higher risk of TMA, which is consistent
with our findings.
None of the case reports addressed the topic of re-introduction of an NSAID after an
episode of TMA. It would be concerning if NSAID use after a TMA episode resulted in
TMA reoccurrence. In our study, we found that 8 (42.1%) exposed cases received a
repeat prescription for NSAIDs in the year following their TMA-associated discharge
date. No patient was re-hospitalized with TMA in the 30 days after the follow-up NSAID
prescription. Thus, these data do not support avoiding NSAID use in patients with a prior
history of TMA.

6.2 Strengths and limitations
Since TMA is a rare event (< 1 per 100,000)21,22,27, our use of large healthcare databases
in the largest province in Canada was opportune as we captured all TMA cases for the
entire province of Ontario over two decades. Methodologically, the case-control design is
considered to be stronger than the case-series design and weaker than the cohort study
design, but we chose to implement the case-control design for this rare disease in order to
identify all available cases and maximize statistical power107 To our knowledge, our
study is the first study to explore an association between NSAIDs and TMA using
population-based administrative data.
However, as with all observational studies, our results are subject to residual
confounding. Even though we controlled for many well-known risk factors for TMA and
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important indications of NSAID use, not all the characteristics are well-coded in our data
sources, which were collected for the primary purpose of healthcare administration rather
than research. To the best of our knowledge, the ICD-9 and ICD-10 codes for TMA have
not yet been validated in any setting. Generally, codes representing administrative data
are typically highly specific, and vary widely in sensitivity.108
The clinical severity of TMA warrants immediate diagnosis and prompt treatment. Most
patients who develop TMA would present to hospital due to acute illness. To reduce the
risk of early mortality, treatment is initiated in hospital upon an early suspicion of
TMA.30,109,110 Without treatment most TMA is fatal. It remains possible that some TMA
goes undiagnosed in routine care, where a patient dies before a diagnosis is made (either
before or during a hospitalization). It is an inherent limitation of this study that such cases
of TMA were not assessed.30
Other consequences that are inevitably associated with the use of administrative data
affected how we defined our outcomes, comorbid conditions, and overall selection of
patients. Furthermore, our data only informs us as to whether the patients had an oral
prescription dispensed, which does not necessarily equate to drug ingested.
One of the biggest challenges in the design of a case-control study is selecting the
appropriate patient population to draw cases and controls.111 We conducted a case-control
study within a population of patients exposed to common pain-indicated drugs, which
would have eliminated some uncertainty around the source we sampled our cases and
controls. However, this approach is not without its flaws. The results obtained from such
a case-control study cannot discriminate an association between the two exposures.112
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Using the results of this study as an example, we obtained a statistically significant odds
ratio that suggests an association exists between NSAIDs and TMA, and this association
was protective. On the other hand, the result can also be interpreted as a harmful
association between acetaminophen and TMA. More research is required before any
conclusions may be drawn regarding the protective association of NSAIDs or the harmful
association with acetaminophen. Nevertheless, our hypothesis had been that a harmful
association would exist between NSAIDs and TMA, with no prior reason to believe
acetaminophen use alters TMA risk. A case-control study of pharmacological
contraceptives presented in Weiss and Koepsell, 2014 utilized a similar study design.112
The study consisted of entirely oral contraceptive users. However, elements of such a
case-control study is commonly found in nested case-control studies, which is
differentiated by the use of incidence-density sampling in selecting matched controls.113
It is important to note that the study is susceptible to inadequate power to detect a true
effect. Larger sample sizes are generally necessary to accurately ascertain a suspected
difference between comparator groups, which is closer to the true effect with increasing
power.114 However, it is also important to note that low power can increase the chance of
observing a statistically significant effect where in truth none had existed.115 The effect
estimate in our primary analysis was statistically significant (95% CI did not cross 1, or
the estimate of no difference in effect). However, the confidence interval was quite wide
(0.16 – 0.84). Wide confidence intervals are a telling feature that the estimates lack
precision and that an analysis likely suffers from low power.116
Another limitation of our study, on the topic of small sample size, is in how we can
control for potential confounders. While we may have deferred to a method of selecting
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confounders based on significance level of each variable (e.g. forward selection,
backwards elimination, or a hybrid method)117, we recognized that we were limited by
our small sample size and placed more reliance on matching to ensure that the
distribution of potential confounders were similar between cases and controls.
Nonetheless, we attempted to control for all potential confounders within the constraints
of a relatively small sample size.
While we included patients of all ages, the majority of information gathered from the
Ontario Drug Benefit database was limited to patients older than age 65. This was
apparent in the median age (71) of our cohort. Therefore, our results may not generalize
to younger age groups.

6.3 Conclusion and future directions
In conclusion, the results of this study did not provide evidence supporting a harmful
association between NSAIDs and TMA.
Historically, case reports and small observational studies have been key to advancing
TMA treatments. Initial observations of TMA symptoms were largely reported in isolated
cases, dating as far back as 1925. Since then there have been a series of studies with
small sample sizes (n<15) noting the efficacy of various treatments, until the literature
began to converge on the success of plasma exchange therapy, eventually leading to a
randomized control trial of 102 TMA patients; this trial clearly demonstrated the
superiority of plasma exchange therapy compared to plasma infusion.118 Convincing
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results from case reports and small observational studies are important for hypothesis
generation and set the precedence for clinical trials. We also believe in the value of
observational studies for identifying strong candidates for biological studies on the
etiology, pathogenesis, and pathophysiology of TMA. Therefore, additional studies on
DITMA in different populations and/or settings could provide further evidence of an
potential association between NSAIDs and TMA, generate hypotheses for future studies,
and strengthen the current state of evidence which consists predominately of case reports.
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Appendices
Appendix A: Search strategy summary
Database
Pubmed

Search strategy

1. Search (((Anti-Inflammatory Agents, NonSteroidal) OR NSAID*))

2. Search ((((Thrombotic Microangiopathy) OR
3.
4.
5.
6.

Embase

Google Scholar

Microangiopathies, Thrombotic) OR
Microangiopathy, Thrombotic))
Search (thrombotic thrombocytopenic purpura)
OR TTP
Search (hemolytic uremic syndrome) OR HUS
2 OR 3 OR 4
1 AND 5

1. Thrombotic microangiopathy.mp. OR thrombotic
thrombocytopenic purpura/
2. Hemolytic uremic syndrome/
3. NSAID.mp. OR nonsteroidal anti-inflammatory
agent/
4. 1 OR 2
5. 3 AND 4
Keyword search using “thrombotic microangiopathy”,
“thrombotic thrombocytopenic purpura”, “hemolytic
uremic syndrome”, “non-steroidal anti-inflammatory”,
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and any alternative representations (e.g. NSAID).
Web of Science

1.
2.
3.
4.
5.
6.
7.
8.

TI=thrombotic thrombocytopenic purpura
TI=Hemolytic uremic syndrome
TS=Thrombotic microangiopathy
TS=NSAID
TS=non-steroidal anti-inflammatory
1 OR 2 OR 3
4 OR 5
6 AND 7

59

Appendix B:
Criteria for evaluation of reports1
1. Clinical or pathologic diagnostic criteria for TMA were present
2. Clinically apparent causes of clinical/pathologic criteria other than TMA and causes of
TMA other than drug toxicity were excluded AND the suspected drug was the only drug
taken or other drugs were continued or restarted
3. TMA resolved or improved when suspected drug stopped or dose reduced (kidney
injury may persist)
4. TMA worsened after suspected drug discontinued OR TMA recurred without
subsequent drug exposure

Levels of evidence for an association of the NSAID induced TMA
Evidence Level

Criteria met
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Level 1 Definite

1, 2, and 3

Level 2 Probable

1 and 2

Level 3 Possible

1

Level 4 Unlikely

1 and 4

Level 52 Not suitable for review due to any one of following:
1. No individual patient data reported
2. Insufficient patient data for assessment
3. Diagnostic criteria for TMA (1) was not met
4. Inappropriate drug dose or non-therapeutic use
5. Drug etiology neither proposed or discussed
6. Combination drug etiology proposed
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1

Criteria for evaluation for this study is based on the criteria for evaluation used in Al-Nouri et al.7 for toxic-mediated drug induced

TMA. Criteria for immune-mediate drug induced TMA was not utilized due to the differences in indication and pharmacological
action between NSAIDs and drugs which are speculated and/or suspected to cause TMA through an immune-mediated mechanism
(e.g. quinine).
2

We did not limit our literature search by language. Therefore, reports with an available English title and reports that were referenced

via other literature were included and reviewed them according to these criteria, where possible. We were unable to review reports
without access to full article.

62

Appendix C: The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in
observational studies using routinely collected health data.

Item

STROBE items

No.

Location in

RECORD items

manuscript where

Location in manuscript
where items are reported

items are reported
Title and abstract
1

(a) Indicate the

Title page, abstract, RECORD 1.1: The type of

study’s design with a

methods

data used should be

commonly used term

specified in the title or

in the title or the

abstract. When possible,

abstract (b) Provide

the name of the databases

in the abstract an

used should be included.

informative and
balanced summary

Title page, abstract, methods
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of what was done
and what was found

RECORD 1.2: If
applicable, the geographic
region and timeframe
within which the study
took place should be
reported in the title or
abstract.

RECORD 1.3: If linkage
between databases was
conducted for the study,
this should be clearly
stated in the title or
abstract.
Introduction
Background
rationale

2

Explain the scientific Introduction
background and

Introduction

64

rationale for the
investigation being
reported
Objectives

3

State specific

Introduction

Introduction

objectives, including
any prespecified
hypotheses
Methods
Methods

Study Design 4

Present key elements

Methods

of study design early
in the paper
Setting

5

Describe the setting,
locations, and
relevant dates,
including periods of
recruitment,
exposure, follow-up,
and data collection

Methods

Methods

65

Participants

6

(a) Cohort study -

Methods

RECORD 6.1: The

Give the eligibility

methods of study

criteria, and the

population selection (such

sources and methods

as codes or algorithms

of selection of

used to identify subjects)

participants.

should be listed in detail.

Describe methods of

If this is not possible, an

follow-up

explanation should be
provided.

Case-control study Give the eligibility
criteria, and the
sources and methods
of case
ascertainment and
control selection.
Give the rationale
for the choice of
cases and controls

RECORD 6.2: Any
validation studies of the
codes or algorithms used
to select the population
should be referenced. If
validation was conducted
for this study and not
published elsewhere,

Cross-sectional

detailed methods and

Methods

66

study - Give the

results should be provided.

eligibility criteria,
and the sources and
methods of selection

RECORD 6.3: If the study

of participants

involved linkage of
databases, consider use of
a flow diagram or other

(b) Cohort study -

graphical display to

For matched studies,

demonstrate the data

give matching

linkage process, including

criteria and number

the number of individuals

of exposed and

with linked data at each

unexposed

stage.

Case-control study For matched studies,
give matching
criteria and the
number of controls
per case
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Variables

7

Clearly define all

Methods, table 2,

RECORD 7.1: A complete

outcomes,

Appendix D

list of codes and

exposures,

algorithms used to classify

predictors, potential

exposures, outcomes,

confounders, and

confounders, and effect

effect modifiers.

modifiers should be

Give diagnostic

provided. If these cannot

criteria, if applicable.

be reported, an explanation

Methods, table 2, appendix D

should be provided.
Data sources/ 8

For each variable of

Appendix D,

measurement

interest, give sources

Methods

of data and details of
methods of
assessment
(measurement).
Describe
comparability of
assessment methods
if there is more than

Appendix D, Methods

68

one group
Bias

9

Describe any efforts

Methods, Results

Methods, Results

Figure 1

Figure 1

Methods, table 2

Methods, table 2

(a) Describe all

Methods, results,

Methods, results, table 2, and

statistical methods,

table 2, and table 3

table 3

to address potential
sources of bias
Study size

10

Explain how the
study size was
arrived at

Quantitative

11

variables

Explain how
quantitative
variables were
handled in the
analyses. If
applicable, describe
which groupings
were chosen, and
why

Statistical
methods

12

69

including those used
to control for
confounding
(b) Describe any
methods used to
examine subgroups
and interactions
(c) Explain how
missing data were
addressed
(d) Cohort study - If
applicable, explain
how loss to followup was addressed
Case-control study If applicable, explain
how matching of
cases and controls
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was addressed
Cross-sectional
study - If applicable,
describe analytical
methods taking
account of sampling
strategy
(e) Describe any
sensitivity analyses
Data access

..

RECORD 12.1: Authors

and cleaning

should describe the extent

methods

to which the investigators
had access to the database
population used to create
the study population.

RECORD 12.2: Authors

Methods

71

should provide
information on the data
cleaning methods used in
the study.
Linkage

..

RECORD 12.3: State

Methods: data sources

whether the study included
person-level, institutionallevel, or other data linkage
across two or more
databases. The methods of
linkage and methods of
linkage quality evaluation
should be provided.
Results
Participants

13

(a) Report the

Figure 1

RECORD 13.1: Describe

numbers of

in detail the selection of

individuals at each

the persons included in the

stage of the study

study (i.e., study

(e.g., numbers

population selection)

Figure 1

72

potentially eligible,

including filtering based

examined for

on data quality, data

eligibility, confirmed

availability and linkage.

eligible, included in

The selection of included

the study,

persons can be described

completing follow-

in the text and/or by means

up, and analysed)

of the study flow diagram.

(b) Give reasons for
non-participation at
each stage.
(c) Consider use of a
flow diagram
Descriptive
data

14

(a) Give

Figure 1, table 2,

characteristics of

methods

study participants
(e.g., demographic,
clinical, social) and
information on
exposures and

Figure 1, table 2, methods

73

potential
confounders
(b) Indicate the
number of
participants with
missing data for each
variable of interest
(c) Cohort study summarise follow-up
time (e.g., average
and total amount)
Outcome
data

15

Cohort study Report numbers of
outcome events or
summary measures
over time
Case-control study Report numbers in

Table 3

Table 3
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each exposure
category, or
summary measures
of exposure
Cross-sectional
study - Report
numbers of outcome
events or summary
measures
Main results

16

(a) Give unadjusted
estimates and, if
applicable,
confounder-adjusted
estimates and their
precision (e.g., 95%
confidence interval).
Make clear which
confounders were
adjusted for and why

Table 3, results

Table 3, results
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they were included
(b) Report category
boundaries when
continuous variables
were categorized
(c) If relevant,
consider translating
estimates of relative
risk into absolute
risk for a meaningful
time period
Other
analyses

17

Report other
analyses done—e.g.,
analyses of
subgroups and
interactions, and
sensitivity analyses

Discussion

Results

Results

76

Key results

18

Summarise key

Results

Results

results with
reference to study
objectives
Limitations

19

Discuss limitations

Discussion

RECORD 19.1: Discuss

of the study, taking

the implications of using

into account sources

data that were not created

of potential bias or

or collected to answer the

imprecision. Discuss

specific research

both direction and

question(s). Include

magnitude of any

discussion of

potential bias

misclassification bias,

Discussion

unmeasured confounding,
missing data, and changing
eligibility over time, as
they pertain to the study
being reported.
Interpretation 20

Give a cautious
overall interpretation

Discussion

Discussion

77

of results
considering
objectives,
limitations,
multiplicity of
analyses, results
from similar studies,
and other relevant
evidence
Generalisabil

21

ity

Discuss the

Discussion

generalisability
(external validity) of
the study results

Other Information
Funding

22

Give the source of
funding and the role
of the funders for the
present study and, if
applicable, for the

Acknowledgements

Acknowledgements

78

original study on
which the present
article is based
Accessibility

..

RECORD 22.1: Authors

ICES data is not available to

of protocol,

should provide

the public as it contains

raw data, and

information on how to

personal medical information

programming

access any supplemental

code

information such as the
study protocol, raw data,
or programming code.

*Reference: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the
RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD)
Statement. PLoS Medicine 2015; in press.
*Checklist is protected under Creative Commons Attribution (CC BY) license.
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Appendix D: Codes

Coding definitions for cohort build and baseline characteristics
Variable

Database

Codes
Cohort Selection

TMA

CIHIDAD

ICD-9: “4466”
ICD-10: “M311”

Plasma Exchange

OHIP

“G272”, “G277”, “G278”, “G290”

NSAIDs

ODB

CELECOXIB, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC
SODIUM & MISOPROSTOL, DIFLUNISAL, ETODOLAC,
FENOPROFEN CALCIUM, FLOCTAFENINE, FLURBIPROFEN,
IBUPROFEN, INDOMETHACIN, KETOPROFEN, KETOROLAC
TROMETHAMINE, MEFENAMIC ACID, MELOXICAM,
NABUMETONE, NAPROXEN, OXAPROZIN, PIROXICAM,
ROFECOXIB, SULINDAC, TIAPROFENIC ACID, TOLMETIN
SODIUM, VALDECOXIB
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Acetaminophen

ODB

ACETAMINOPHEN & CODEINE PHOSPHATE, ACETAMINOPHEN &
CAFFEINE & CODEINE PHOSPHATE

Dilaudid

ODB

HYDROMORPHONE, HYDROMORPHONE HCL

ACE inhibitors

ODB

BENAZEPRIL CHLOROHYDRATE, BENAZEPRIL HCL, CAPTOPRIL,
CILAZAPRIL, ENALAPRIL SODIUM, FOSINOPRIL, FOSINOPRIL
SODIUM, LISINOPRIL, PERINDOPRIL TERT.BUTYLAMINE,
QUINAPRIL, RAMIPRIL, TRANDOLAPRIL
Baseline comorbidities

Cancers

CIHI-

ICD9 (CIHI-DAD): "150", "154", "155", "157", "162", "174", "175", "185",

DAD

"203", "204", "205", "206", "207", "208", "2303", "2304", "2307", "2330",
"2312", "2334"

OHIP
IDC10 (CIHI-DAD): "971", "980", "982", "984", "985", "986", "987",
"988", "989", "990", "991", "993", "C15", "C18", "C19", "C20", "C22",
"C25", "C34", "C50", "C56", "C61", "C82", "C83", "C85", "C91", "C92",
"C93", "C94", "C95", "D00", "D05", "D010", "D011", "D012", "D022",
"D075"
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OHIP DX: "203", "204", "205", "206", "207", "208", "150", "154", "155",
"157", "162", "174", "175", "183", "185"
Kidney transplant

CORR

CORR:

OHIP

RECIPIENT_TREATMENT dataset
[Treatment_Code]: 171
[Treatment_Date]
[Transplanted_Organ_Type_Code][1-3]: "10", "11", "12", "18", "19"
CCP: "6759"
CCI: "1PC85"
OHIP feecode: "S435", "S434"

Rheumatoid arthritis

ICD9: "714"
ICD10: "M05", "M06"
OHIP Dx: "714"
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Osteoarthritis

CIHI-

ICD9: "715"

DAD
ICD10: "M15", "M150", "M151", "M152", "M153", "M154", "M158",
"M159"
Malignant hypertension

CIHI-

ICD9: "4010"

DAD
ICD10: "I101"
Systemic lupus

CIHI-

erythematosus

DAD

ICD9: "7100"
ICD10: "M320", "M321", "M328", "M329"

HIV

CIHI-

ICD9 (CIHI-DAD): "042", "043", "044", "176"

DAD
ICD10 (CIHI-DAD): "B24", "Z21", "C46"
OHIP
OHIP DX: "042", "043", "044"
Sepsis

CIHI-

ICD9: "0031", "0362", "0380", "0381", "0382", "0383", "03840", "038.41",

DAD

"03842", "03843", "03844", "03849", "0388", "0389"
ICD10: "A40", "A41"
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TMA: Thrombotic microangiopathy, NSAIDs: non-steroidal anti-inflammatory drugs, ICD: International Classification of Diseases,
CIHI-DAD: Canadian Institute for Health Information – Discharge Abstract Database, OHIP: Ontario Health Insurance Plan, CORR:
Canadian Organ Replacement Register, CCI: Canadian Classification of Health Interventions, CCP: Canadian Classification of
Diagnostic, Therapeutic and Surgical Procedures, ACE: angiotensin-converting enzyme, HIV: Human Immunodeficiency Vir
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Appendix E: Flow diagram of patient selection with angiotensin-converting enzyme
inhibitors as referent group
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Appendix F: Baseline characteristics for patients prescribed NSAIDs1 or ACEinhibitors1 with and without thrombotic microangiopathy (cases and controls,
respectively)

Controls

Cases
P-value4

(n=336)

(n=84)

Demographics

Age, no. (%)
Median (IQR)

74 (68-81)

74 (67-82)

Mean ± SD

73 ± 10.4

73 ± 11.13

≤ 17

0.22

0

18 - 44

0
21 (6.3%)5

35 - 44

≤5

16 - 54

≤5
0.41

55 - 64

20 (6%)

7 (8.3%)

65 - 74

140 (41.7%)

37 (44%)

75 - 84

112 (33.3%)

22 (26.2%)

≥ 85

43 (12.8%)

13 (15.5%)

Female, no. (%)

200 (59.5%)

50 (59.5%)

1.0

Rural location, no. (%)2

56 (16.7%)

14 (16.7%)

1.0

Socioeconomic status, no. (%)3
Quintile 1

72 (21.4%)

18 (21.4%)

1.0

Quintile 2

56 (16.7%)

14 (16.7%)

1.0
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Quintile 3

56 (16.7%)

14 (16.7%)

1.0

Quintile 4

72 (21.4%)

18 (21.4%)

1.0

Quintile 5

80 (23.8%)

20 (23.8%)

1.0

Primary care physician visits, no. (%)
Median (IQR)

8 (5-13)

12 (7-19)

Mean ± SD

11 ± 11.26

16 ± 14.23

0

16 (4.8%)

≤5

1-2

34 (10.1%)

8 (9.5%)

3-4

54 (16.1%)

≤5

5-6

54 (16.1%)

6 (7.1%)

7-8

37 (11%)

9 (10.7%)

<0.01

<0.01

<0.01
9 - 10

38 (11.3%)

9 (10.7%)

≥ 11

103 (30.7%)

47 (56%)

Comorbidities, no. (%)
John Hopkins ADG Score, no. (%)
Median (IQR)

11 (8-14)

13.5 (11-16)

Mean ± SD

11 ± 4.19

13 ± 3.68

≤9

122 (36.3%)

12 (14.3%)

10 - 12

92 (27.4%)

23 (27.4%)

<0.01

<0.01
13 - 15

62 (18.5%)

22 (26.2%)

≥ 16

60 (17.9%)

27 (32.1%)

Malignant hypertension

≤5

≤5

-

Systemic lupus erythematosus

≤5

≤5

-
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Cancer

32 (9.5%)

12 (14.3%)

<0.01

Renal transplant

≤5

≤5

-

Osteoarthritis

11 (3.3%)

≤5

<0.01

Rheumatoid arthritis

18 (5.4%)

9 (10.7%)

<0.01

HIV1

≤5

≤5

1.0

Sepsis

Suppressed5

≤5

1.0

Medications, no. (%)

1no.:

Quinine

≤5

≤5

-

Quetiapine

≤5

≤5

-

Tacrolimus

≤5

≤5

-

Sirolimus

≤5

≤5

-

Cyclosporine

≤5

≤5

-

Clopidogrel

≤5

≤5

-

Ticlopidine

≤5

≤5

-

Number, IQR: interquartile range, SD: Standardized difference, NSAIDs: non-steroidal anti-inflammatory drugs,
ACE: angiotensin-converting enzyme, HIV: Human immunodeficiency virus
2Rural residence is defined as population < 10,000
3Quntiles are ranked from lowest to highest (i.e. Quintile 1 = lowest, Quintile 5 = highest)
4P-values are calculated using generalized estimating equations
5cells are combined or suppressed to avoid reporting numbers ≤5
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Appendix G: The association between NSAID use and thrombotic microangiopathy,
with ACE inhibitors as a reference group. Odds ratios derived from a conditional logistic
regression model.

Cases of TMA

Controls

n=84

n=336

ACE inhibitors2

66 (79%)

NSAIDs2

18 (21%)

Odds Ratio (95% confidence interval)
Unadjusted

Adjusted1

253 (75%)

1.0 (referent)

1.0 (referent)

83 (25%)

0.82 (0.45-1.49)

0.72 (0.38-1.37)

1Adjusted analysis included the following variables: cancer, osteoarthritis, rheumatoid arthritis, John Hopkin’s ADG
score and primary care physician visits
2NSAIDs:

Non-steroidal anti-inflammatory drugs, ACE: angiotensin-converting enzyme
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